Saved in this browser. Sign in to sync across devices.
Important distinction: No mandatory routine post-injection observation is required for WELTRUZA, unlike the older intramuscular olanzapine depot. That does not mean post-injection delirium/sedation syndrome (PDSS) is impossible. FDA requested enhanced reporting and evaluation of PDSS cases for the first five years after approval.
What the FDA approved
The FDA approved WELTRUZA (olanzapine) extended-release injectable suspension on October 8, 2026, for schizophrenia in adults. A healthcare professional injects it under the skin of the abdomen once monthly. It is a different formulation and route from the older intramuscular olanzapine long-acting injection. The label calls for establishing oral olanzapine tolerability first if it has not already been demonstrated.
REGULATORY STATUS
FDA-approved
Approved for adults with schizophrenia, not for dementia-related psychosis, autism, ADHD or other uses without separate supporting authorization.
DELIVERY
Once monthly
Clinician-administered subcutaneous injection. The approval does not require loading doses, supplemental oral medication after initiation or routine post-injection observation.
EFFICACY EVIDENCE
SOLARIS, Phase 3
The company reported symptom and functioning improvements in its pivotal randomized eight-week study of 675 adults; this is not a head-to-head proof of superiority over every other antipsychotic.
SAFETY
Monitoring remains essential
Weight, blood glucose, lipids, sedation, movement symptoms, blood pressure and other adverse effects remain important parts of clinical follow-up.
How is it different from daily pills?
Some people and families prefer treatment that does not rely on remembering a tablet every day. Other people prefer oral options, different long-acting medicines or a plan that allows different types of dose adjustments. Choice depends on treatment history, side effects, personal preferences, injection access and clinician judgment. A monthly schedule is a practical difference, not proof of better outcomes for every person.
What are the important risks?
The prescribing information includes a boxed warning about increased mortality in older adults with dementia-related psychosis and cautions about metabolic changes (including weight gain, high blood sugar and lipid changes), somnolence, movement disorders and other serious reactions. WELTRUZA is not approved for dementia-related psychosis.
PDSS—excessive drug exposure with sedation, confusion or other serious symptoms—has occurred with another intramuscular olanzapine formulation. The approved label says it is unknown whether PDSS can occur with WELTRUZA. Absence of a required observation period is not a guarantee of no such event. Emergency evaluation is appropriate for severe confusion, loss of consciousness or other possible overdose symptoms after an injection.
Related study: GLP-1 medicines and psychiatric care
A 2026 observational cohort of adults with both schizophrenia and type 2 diabetes found an association between GLP-1 treatment initiation and fewer psychiatric hospital and emergency visits. That research did not specifically test WELTRUZA, show GLP-1 medicines prevent olanzapine-related metabolic complications, or establish GLP-1 medicines as schizophrenia treatments.
Read the study and its limitations →Questions for a prescriber
- Is this formulation appropriate given current symptoms, previous olanzapine response and side-effect history?
- How should weight, blood glucose, lipid levels, blood pressure, movement symptoms and sedation be monitored?
- What should happen if an appointment or monthly injection is missed?
- What warning symptoms after an injection should prompt urgent assessment?
- How do injection-site visits, insurance access and costs compare with other treatment options?
Approved does not mean right for everyone
Medication decisions belong with the treating psychiatric team. Never stop, switch or change the dose of an antipsychotic based on a research headline or a comparison website.
Original FDA documents and trial context
- FDA — NDA 219007 approval letter (October 8, 2026) ↗
Primary regulatory source, including requested enhanced postmarketing PDSS surveillance.
- FDA — WELTRUZA full prescribing information (October 2026) ↗
Official approved indication, dosing and safety information; refer to current labeling with a clinician.
- Teva — FDA approval and SOLARIS trial summary (October 9, 2026) ↗
Manufacturer's summary of trial findings and intended launch; not an independent comparative effectiveness study.
Evidence and links rechecked October 20, 2026. Educational editorial draft; independent clinical review pending. Check the most recent FDA labeling for updates.